NEW YORK (GenomeWeb News) – Exact Sciences has submitted the third and final module of its premarket approval application to the US Food and Drug Administration for its Cologuard colorectal cancer screening test, the company said today.
Registering provides access to this and other free content.
Already have an account?Login Now.
Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.
In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.
President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.
Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.
This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.